Simon White, M.D.

He/Him | PGY-2 @nyuuroresidency | @DukeU 2019 | @MedicineUVA 2024| Urologist in training

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

📐 HR 0.68 = a 32% relative risk reduction in recurrence at any given moment during follow-up.

That sounds like a large benefit.
But the absolute numbers tell a different story:

BCG alone: 81.6% disease-free at 2 years
BCG + durvalumab: 86.5% disease-free at 2 years

Absolute difference: ~5%

Since BCG already works well, a big relative reduction maps to a modest absolute gain. @MaxKates @UrogerliMD @JoshMeeks

[NYU Urology Residency @NYUUROresidency]

@NYUUrology represents! Thank you to @NYSAUA for hosting the annual Valentine Essay Contest yesterday. Great catching up with friends and colleagues…

[NYU Urology Residency @NYUUROresidency]

Congratulations to Samuel Carbunaru and Vyom Sawhney, our stellar NYU Langone residents, on your awards for original research presented at the @NYSAUA Valentine essay contest last night! 🎉👍🏅

[Amr Elbakry @AmrElbakryUro]

I’ve been trying maturing stoma first before ureter anastomosis for intracorporeal IC like I used to do in open. Easier to place diversion stents. Also no question about any potential tension on ureter anastomosis after maturing the stoma @lee_c_zhao @WVU_Urology @IFRUEUrol

[UChicago Urology Residency @UChicagoUro]

Apply to our MATTER program which provides a $2k stipend for visiting sub-Is ⬇️

Visit for more information: https://t.co/5skMzxXNAe

[Andrea Apolo, M.D. @apolo_andrea]

The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26

[Lee Zhao @lee_c_zhao]

In 1980, DeBakey operated on the Shah of Iran. He declares success. Soon, the patient is dead. Reoperation is psychologically brutal: how bias delay truth & what might save us from the same trap. https://t.co/5nZdjJEcmA #MedTwitter #Surgery #MedEd

[NYU Urology Residency @NYUUROresidency]

NYU Langone Urology is thrilled to welcome four new members to our team! Congratulations to all who matched successfully this year!

[Simon White, M.D. @simonwhitemd]

@AmrElbakryUro @lee_c_zhao @NYUUrology 🐐!!! You’re best man - will miss you, best of luck on your journey!

[Jesse Persily @JPersily]

Could not be more ecstatic to follow in the footsteps of some @NYUUrology giants and train at @UTSWUrology for @SUO_YUO fellowship. Beyond grateful for everyone who has helped along the journey! @KSMurrayUro @UroWCH @tanejauro @DrTanWP @wysock

[Simon White, M.D. @simonwhitemd]

@MansaBarrie This is what I’m talking about! More kidney stuff less brain stuff!

[Wei Phin Tan, MD, MHS, FACS @DrTanWP]

Huge congrats to the bossman on receiving the 2025 Ferdinand C. Valentine Medal — a well-deserved honor for a true legend in the field. Proud to see him standing among giants (and holding his own). @NYSAUA @AmerUrological @nyugrossman @NYUUrology @nyulangone

[NYU Urology Residency @NYUUROresidency]

Congratulations to Walter Roper for 1st place poster and Vyom Sawhney for 3rd place podium at the NY Section AUA Valentine Research contest! What a day for NYU Langone!

[Ari Bernstein, M.D. @ari_bernstein]

In the home stretch @NYUUrology with this crew! @NYSAUA

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫
@nirmishsingla @AdityaBagrodia 
Dr #EzraBaraban @yalepathology @CDFankhauser @yasserged @JAMA_current @OncoAlert

💡 Key Insights:
🧬 Epidemiology & Risk Factors
🔹 Most common solid malignancy in men aged 15-40
🔹 ~10,000 cases annually in the U.S.
🔹 Risk factors: Cryptorchidism, family history, infertility, cannabis use, Klinefelter syndrome

🩺 Clinical Presentation & Diagnosis
🔹 Painless testicular mass is the most common symptom
🔹 Diagnosis: Scrotal ultrasound + tumor markers (AFP, β-hCG, LDH)

📊 Staging & Treatment
🔹 Stage I (70-75%): Orchiectomy + surveillance or adjuvant therapy 🏥
🔹 Stage II (20%): Lymph node involvement, treated with chemo, RPLND, or RT
🔹 Stage III (10%): Distant metastases → BEP/EP/VIP chemotherapy 💉

🎯 Survival & Long-term Effects
🔹 5-year survival rates: 99% (Stage I), 92% (Stage II), 85% (Stage III)
🔹 Long-term effects: Cardiovascular disease, secondary malignancies, infertility, hypogonadism, psychosocial impact

🧪 Emerging Biomarkers & Future Directions
🔹 miR-371a-3p: High sensitivity (91%) & specificity (94%) for early detection
🔹 Research is ongoing to refine risk stratification & de-escalate treatment
@UCSD_Urology @UCSDCancer @UCSDHealth @DrRanaMcKay @MadamSurgeonMD @cjkane10 @endourologyucsd
@JohnsHopkinsUni1
#OncoUrology #TesticularCancer #UroOncology #OncoTwitter #CancerResearch #MedicalOncology https://t.co/5GJxRea7ZO

[UVA Surgery @UVASurgery]

Happy to announce this collaboration between @UVASurgery and @uvaurology for qualified candidates.

Let’s find a match

@cmf2x @KGUROmd

#urologymatch2025

[NYU Urology Residency @NYUUROresidency]

Congratulations to these superstars 🌟! We are thrilled to welcome you to our NYU Langone Urology family!

[UVA Urology @uvaurology]

Attention med students‼️ We are offering a one-year paid research fellowship! This program is targeted towards 3rd & 4th year students or those who have recently gone unmatched in the Urology Match process. Click the link below for more details⬇️
https://t.co/7Dypx6Wf7C

[Simon White, M.D. @simonwhitemd]

@DrDenise_ @UChicagoUrology Congrats!!!

[Samir Taneja @tanejauro]

Looking for applicants interested in a one or two yr urologic oncology fellowship @NYUUrology. High volume of robotic surgery, PCa focal therapy, imaging, and multidisciplinary care. Formal research training/masters degree in the 2 yr model. If interested, DM me!